Challenges in the Treatment of Invasive Aspergillosis in Immunocompromised Children.

TitleChallenges in the Treatment of Invasive Aspergillosis in Immunocompromised Children.
Publication TypeJournal Article
Year of Publication2022
AuthorsHsu AJ, Tamma PD, Fisher BT
JournalAntimicrob Agents Chemother
Paginatione0215621
Date Published2022 Jun 29
ISSN1098-6596
Abstract

Invasive aspergillosis (IA) is associated with significant morbidity and mortality. Voriconazole remains the drug of choice for the treatment of IA in children; however, the complex kinetics of voriconazole in children make dosing challenging and therapeutic drug monitoring (TDM) essential for treatment success. The overarching goal of this review is to discuss the role of voriconazole, posaconazole, isavuconazole, liposomal amphotericin B, echinocandins, and combination antifungal therapy for the treatment of IA in children. We also provide a detailed discussion of antifungal TDM in children.

DOI10.1128/aac.02156-21
Alternate JournalAntimicrob Agents Chemother
PubMed ID35766509